Are patients on somatostatin analogue therapy receiving high quality holistic cancer nursing care?

#4295

Introduction: SSA is indicated for the treatment of G1 and some G2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin in adult patients with unresectable locally advanced or metastatic disease. As these types of cancer have much lower proliferation rates than common cancers, they are not exclusively considered cancer. It is hypothesised these patients may subsequently receive sub-standard cancer care. Furthermore, patients who are diagnosed with metastatic G3 neuroendocrine cancers will require systemic treatment with significant side effect profiles impacting negatively on quality of life.

Aim(s): To explore the generic needs of people living with cancer and demonstrate how these apply also to patients with GEP-NET. Provide examples of holistic needs assessment tools.

Materials and methods: Review of diagnosis and treatment outcomes for patients referred to Cancer Centre 2022 - 2023 focussing on those with metastatic disease across all grades. Measurement of symptom burden in patients with metastatic disease. Number of patients considered to have incurable disease and referral for financial assessment and fast track monetary benefits arranged.

Conference:

Presenting Author:

Authors: Wotherspoon I,

Keywords: Cancer nursing,